单位：[1]Department of Microbiology, School of Basic Medical Sciences, CapitalMedical University, Beijing 100069, China[2]Zhuhai SanMed Biotech Ltd, Zhuhai519000, China[3]Joint Research Center of Liquid Biopsy in Guangdong, HongKong and Macau, Zhuhai 519000, China[4]Department of General Surgery,China-Japan Friendship Hospital, 100029 Beijing, China[5]Institute of ClinicalMedical Sciences, China-Japan Friendship Hospital, 100029 Beijing, China
Joint Project of BRC-BC (Biomedical Translational Engineering Research Center of BUCT-CJFH) [XK2020-09]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81871641, 81972979, U1902210, U1602223]; Scientific Research Plan of Beijing Municipal Education Committee [KM201710025002]; Key Project of Beijing Natural Science FoundationBeijing Natural Science Foundation [KZ201810025035]; Support Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan [IDHT20190510]
第一作者单位：[1]Department of Microbiology, School of Basic Medical Sciences, CapitalMedical University, Beijing 100069, China
通讯作者：
推荐引用方式(GB/T 7714)：
Wang Pei-Gang,Tang Dong-Jiang,Hua Zhan,et al.Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation[J].CELL DISCOVERY.2020,6(1):doi:10.1038/s41421-020-00217-2.
APA：
Wang Pei-Gang,Tang Dong-Jiang,Hua Zhan,Wang Zai&An Jing.(2020).Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation.CELL DISCOVERY,6,(1)
MLA：
Wang Pei-Gang,et al."Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation".CELL DISCOVERY 6..1(2020)
生物学